Research Type: Extramural
We are pleased to announce the recipient of the 2025 Sally Crossing AM Award, Professor Keall, who leads the Image X Institute at the University of Sydney, for engaging consumers throughout his research which has positively impacted the lives of millions of cancer patients.
Professor Selth and his team have developed a new CDK inhibitor, called AU2-94. Preliminary evidence suggests that AU2-94 effectively blocks growth of breast and prostate cancer cells without causing significant toxicity.
Dr Cohen and his team have identified two small-molecule drugs that inhibit the action of telomerase, and this project aims to advance the efficacy and safety of these drugs.
Dr Teh and her team are developing a novel approach to immunotherapy that targets a different type of white blood cell, called a regulatory T cell. This project aims to target ‘suicide genes’ to kill regulatory T cells that are surrounding the tumour.
Dr Hindley and his team are developing a technology called Voxelmap that can track the movement of tumours and organs in real-time in lung cancer patients receiving hypofractionated radiation therapy.
Professor Hondermarck and his team aim to enhance the efficacy of current Glioblastoma treatments by repurposing a drug that is already in clinical trials for its ability to protect the nervous system from damage.
Associate Professor Vittorio and his team discovered that brain cancers, such as DIPG, are addicted to copper and that using non-toxic drugs to reduce the levels of copper can kill the cancer cells.
Professor Pimanda and his team have discovered that there are key differences in the cancer cells between patients who respond to chemotherapy compared to those who don’t.
This project will repurpose an existing cancer drug, Entrectinib, to treat HER2+ breast cancers that are resistant to current anti-HER2 targeted therapies.
Dr Koay and her team are developing a novel type of immunotherapy which targets a specialised subset of T-cells which possess the potential to attack cancer more effectively than existing T-cell immunotherapies.